Abstract 4365135: Concomitant Pulsed Field Ablation and Left Atrial Appendage Closure Using WATCHMAN FLX Pro: A Preclinical Evaluation of Procedural Compatibility and Tissue Response

C Charbel Noujaim (Tulane Univeristy, New Orleans, Louisiana, United States) W Wael Jaber (Cleveland Clinic Coordinating Center for Clinical Research, Heart Vascular Thoracic Institute, Cleveland Clinic, Cleveland) A Andrea Natale (Texas Cardiac Arrhythmia Research, St. David’s Medical Center, Austin) D David De Lurgio (EmoryHealthcare, Atlanta, Georgia, United States) B Brad Mikaelian (Memorial Hospital, Colorado Springs, Colorado, United States) A Austin Caldwell (Boston Scientific, Saint Paul, Minnesota, United States) C Caroline Baldo (Boston Scientific, Saint Paul, Minnesota, United States) E Erin Hynes (Boston Scientific, Saint Paul, Minnesota, United States) W Walid Saliba (CLEVELAND CLINIC, Cleveland, Ohio, United States)

Abstract

Background: Pulsed field ablation is a novel non-thermal energy source for pulmonary vein isolation that offers potential procedural and safety advantages over thermal modalities. However, its acute anatomical effects and compatibility with same-session left atrial appendage closure remain insufficiently characterized. Objective: To evaluate the feasibility, safety, and anatomical response of combining PFA-based PVI with LAAC using the WATCHMAN FLX Pro device in a healthy canine model. Methods: Nine canines underwent PVI with either PFA (n=6) or radiofrequency ablation (RFA; n=3), followed by LAAC with the WATCHMAN FLX Pro in a single session. Procedural success, tissue remodeling, device compression, and peri-device leaks were assessed using serial transesophageal echocardiography and computed tomography over a 45-day period, with terminal pathological analysis. Results: All procedures were completed without complications, and LAAC met PASS criteria in all animals. TEE confirmed complete seal at implant and at 45 days in both groups. PFA was associated with greater post-ablation reduction in LAA diameters and significantly higher device compression (23±8% vs. 13±4% by TEE) despite smaller average device sizes. CT demonstrated greater early compression loss in the PFA group, with gradual recovery by Day 45. Two minor peri-device leaks (<5 mm) were identified on CT in the PFA group only. Ridge edema and anatomical remodeling were pronounced acutely in the PFA group but resolved by 45 days. No thrombus, embolic events, or device dislodgement occurred at any point during the study. Conclusion: In this preclinical study, the combination of PFA and LAAC using the WATCHMAN FLX Pro device was feasible and acutely safe. PFA was associated with greater acute anatomical remodeling compared to RFA, including more pronounced tissue edema and device compression. These changes resolved over time without compromising device seal or position. Small peri-device leaks (<5 mm) were observed on follow-up CT but not TEE imaging in the pulsed field ablation group only. Further studies are warranted to assess the long-term implications of PFA–associated remodeling and its potential impact on device performance.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (9)

C

Charbel Noujaim

Tulane Univeristy, New Orleans, Louisiana, United States

W

Wael Jaber

Cleveland Clinic Coordinating Center for Clinical Research, Heart Vascular Thoracic Institute, Cleveland Clinic, Cleveland

A

Andrea Natale

Texas Cardiac Arrhythmia Research, St. David’s Medical Center, Austin

D

David De Lurgio

EmoryHealthcare, Atlanta, Georgia, United States

B

Brad Mikaelian

Memorial Hospital, Colorado Springs, Colorado, United States

A

Austin Caldwell

Boston Scientific, Saint Paul, Minnesota, United States

C

Caroline Baldo

Boston Scientific, Saint Paul, Minnesota, United States

E

Erin Hynes

Boston Scientific, Saint Paul, Minnesota, United States

W

Walid Saliba

CLEVELAND CLINIC, Cleveland, Ohio, United States